The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

Abstract Background Mechanisms by which Smac mimetics (SMs) interact with proteasome inhibitors (e.g., bortezomib) are largely unknown, particularly in multiple myeloma (MM), a disease in which bortezomib represents a mainstay of therapy. Methods Interactions between the clinically relevant IAP (inh...

Full description

Bibliographic Details
Main Authors: Liang Zhou, Yu Zhang, Yun Leng, Yun Dai, Maciej Kmieciak, Lora Kramer, Kanika Sharma, Yan Wang, William Craun, Steven Grant
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Journal of Hematology & Oncology
Subjects:
Multiple myeloma
IAP antagonist
Bortezomib
NF-κB
Online Access:http://link.springer.com/article/10.1186/s13045-019-0713-x

Internet

http://link.springer.com/article/10.1186/s13045-019-0713-x

Similar Items